Exabis Library
Welcome to the e-CCO Library!
P461: Endoscopic features for loss of response in patients with Crohn’s disease who were treated with infliximab by top-down strategy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P461: Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P461: Rapid response to appendectomy in the majority of patients with refractory Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P461: Vedolizumab Dose Escalation in a Real-World Cohort of IBD Patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P462 Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn’s disease. Data from clinical practice from the eneida registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P462: Adalimumab improves treatment satisfaction with medication and work productivity amongst patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P462: Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early Responders
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P462: Dietary restrictions on inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P462: Impact of teduglutide, a GLP-2 agonist, on inflammatory bowel disease-associated short bowel syndrome: a tertiary single-center study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P462: Long-term outcomes of anti-TNF therapy discontinuation in patients with penetrating Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P462: Mucosal healing and deep remission rates with azathioprine in inflammatory bowel disease?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P462: Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P463 Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P463: Combination therapy of fresh faecal microbial transplantation and antibiotics for ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P463: COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey of the Italian IBD patients’ association (AMICI Onlus).
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P463: Crohn's disease–associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P463: Factors to determine prognosis of intestinal cancer associated with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P463: Long-term effects of anti-TNF therapy on bone metabolism
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P463: Recurrence of Crohn's disease after the first surgical intervention
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P463: Serum and mucosal Serpin E1 concentration correlates with endoscopic activity in inflammatory bowel disease - potential new activity marker
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM